ArticleAnnals of clinical and translational neurology2026
Early Clinical and Cerebrospinal Fluid Predictors of 1-Year Recurrence in Autoimmune GFAP Astrocytopathy.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAutoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is an inflammatory central nervous system disorder with variable outcomes. Relapse occurs in a subset of patients, but early predictors remain unclear. We aimed to identify admission-available features associated with 1-year recurrence and develop an interpretable risk stratification model.
methodsWe retrospectively included 156 patients with CSF GFAP-IgG-positive GFAP-A between January 2021 and February 2025. Patients were classified by recurrence within 1 year. Early demographic, clinical, CSF, serological, neuroimaging, and treatment-related variables were compared between groups. Candidate predictors were screened using elastic net regression with repeated cross-validation, followed by multivariable logistic regression and internal validation.
resultsThirty-five patients (22.4%) relapsed within 1 year. Patients with and without recurrence within 1 year were broadly comparable in age, sex, baseline severity, neuroimaging findings, and treatment exposure. Patients with recurrence within 1 year had lower CSF white blood cell counts (42.0 [10.0-104.0] vs. 107.0 [34.0-200.0] × 10
interpretationIn GFAP-A, 1-year recurrence was associated with distinct early clinical and CSF features rather than baseline severity or treatment exposure alone. This admission-based model may support recurrence risk stratification and follow-up planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.